186 related articles for article (PubMed ID: 30788859)
1. Response to vedolizumab for children with steroid-refractory Ulcerative Colitis unresponsive to anti-TNF.
Wiskin AE; Paul SP; Spray CH
Acta Paediatr; 2019 Jul; 108(7):1359-1360. PubMed ID: 30788859
[No Abstract] [Full Text] [Related]
2. Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease.
Schneider AM; Weghuber D; Hetzer B; Entenmann A; Müller T; Zimmermann G; Schütz S; Huber WD; Pichler J
BMC Gastroenterol; 2018 Sep; 18(1):140. PubMed ID: 30219028
[TBL] [Abstract][Full Text] [Related]
3. Successful Vedolizumab Therapy in a Sixteen-Year-Old Boy with Refractory Ulcerative Colitis.
Zoet ID; de Boer NK; de Meij TG
J Crohns Colitis; 2016 Mar; 10(3):373-4. PubMed ID: 26574489
[No Abstract] [Full Text] [Related]
4. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
5. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
6. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
7. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
8. Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.
Farkas K; Molnár T; Szepes Z
Expert Rev Gastroenterol Hepatol; 2014 Aug; 8(6):695-702. PubMed ID: 24738535
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
[TBL] [Abstract][Full Text] [Related]
10. Should we use vedolizumab as mono or combo therapy in ulcerative colitis?
Hedin C; Halfvarson J
Best Pract Res Clin Gastroenterol; 2018; 32-33():27-34. PubMed ID: 30060935
[TBL] [Abstract][Full Text] [Related]
11. Using Vedolizumab to Treat Severe Sweet's Syndrome in a Patient With Ulcerative Colitis.
Belvis Jiménez M; Maldonado Pérez B; Argüelles-Arias F
J Crohns Colitis; 2018 Aug; 12(9):1134-1135. PubMed ID: 29788419
[No Abstract] [Full Text] [Related]
12. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
13. A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis.
Tsai HH; Black C
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):679-683. PubMed ID: 27726457
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 acquisition in a man with ulcerative colitis on anti-α4β7 mAb vedolizumab treatment.
Gunst JD; Schleimann MH; Pahus MH; Østergaard L; Tolstrup M; Søgaard OS
AIDS; 2020 Sep; 34(11):1689-1692. PubMed ID: 32769767
[No Abstract] [Full Text] [Related]
15. Nodular vasculitis during treatment with vedolizumab in a patient with ulcerative colitis.
Abbenante D; Merli Y; Misciali C; Sacchelli L; Bardazzi F
Australas J Dermatol; 2022 Feb; 63(1):131-132. PubMed ID: 34817061
[No Abstract] [Full Text] [Related]
16. Vedolizumab for the Induction of Remission in Treatment-refractory Microscopic Colitis in a Pediatric Patient.
Wenzel AA; Strople J; Melin-Aldana H; Brown JB
J Pediatr Gastroenterol Nutr; 2020 Jul; 71(1):e47-e48. PubMed ID: 32304548
[No Abstract] [Full Text] [Related]
17. The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Colombel JF; Sands BE; Rutgeerts P; Sandborn W; Danese S; D'Haens G; Panaccione R; Loftus EV; Sankoh S; Fox I; Parikh A; Milch C; Abhyankar B; Feagan BG
Gut; 2017 May; 66(5):839-851. PubMed ID: 26893500
[TBL] [Abstract][Full Text] [Related]
18. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis?
Pouillon L; Van Stappen J; Bossuyt P; Danese S; Peyrin-Biroulet L
Best Pract Res Clin Gastroenterol; 2018; 32-33():17-25. PubMed ID: 30060934
[TBL] [Abstract][Full Text] [Related]
19. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?
D'Amico F; Danese S; Peyrin-Biroulet L
Expert Opin Biol Ther; 2020 Apr; 20(4):353-361. PubMed ID: 31951748
[No Abstract] [Full Text] [Related]
20. Early Assessment With Gastrointestinal Ultrasound in Patients Hospitalised for a Flare of Ulcerative Colitis and Predicting the Need for Salvage Therapy: A Pilot Study.
Smith RL; Taylor KM; Friedman AB; Swaine AP; Gibson DJ; Gibson PR
Ultrasound Med Biol; 2021 Apr; 47(4):1108-1114. PubMed ID: 33413967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
